华纳药厂参与国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including montmorillonite powder, being proposed for selection in this procurement process [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]